Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 9/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4971071 | 0.87 | CA2 (0.53) | CA2BRD4CREBBPGSK3BALDH1A1 | |
| SCHEMBL4969066 | 0.80 | CA2 (0.54) | CA2BRD4CREBBPGSK3BALDH1A1 | |
| SCHEMBL4968241 | 0.76 | CA2 (0.53) | CA2BRD4CREBBPGSK3BNR3C1 | |
| SCHEMBL4971366 | 0.73 | BRD4 (0.45) | BRD4ALDH1A1HPGDKMT2ACHRM1 | |
| SCHEMBL4970052 | 0.73 | BRD4 (0.45) | BRD4ALDH1A1HPGDKMT2ACHRM1 | |
| SCHEMBL4970074 | 0.73 | BRD4 (0.45) | BRD4ALDH1A1HPGDKMT2ACHRM1 | |
| SCHEMBL4970806 | 0.73 | BRD4 (0.55) | CA2BRD4CREBBPGSK3BNR3C1 | |
| SCHEMBL4970322 | 0.71 | ATM (0.38) | PGRKMT2AATM | |
| SCHEMBL4969420 | 0.70 | CA2 (0.53) | CA2BRD4CREBBPGSK3BALDH1A1 | |
| SCHEMBL2363289 | 0.70 | BRD4 (0.61) | CA2BRD4CREBBPGSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1985297-A1 | CARBOXYLIC ACID COMPOUND AND USE THEREOF | Japan Tobacco, Inc. (JP) | 2008-10-29 | — | — | EP | disclosed |
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | JAPAN TOBACCO INC. (JP) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197512-A1 | Carboxylic Acid Compounds and Use Thereof | GLS, SLC10A1, SOAT1 | CA2 363/4885BRD4 3303/4885CREBBP 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.